SWOG clinical trial number
30904

A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma

Closed
Phase
Published
Abbreviated Title
Renal
Activated
05/15/2000
Closed
01/13/2003
Participants
NCORP, Members, UCOP, Medical Oncologists, Surgeons, Pathologists

Research committees

Genitourinary Cancer

Eligibility Criteria Expand/Collapse

Pt must have solitary T1-T2 renal tumors, suspicious for renal adenocarcinoma in the presence of a normal contralateral kidney. Tumor must be well located so that surgery can be safely done in healthy tissue; should not exceed 5 cm in diameter; must be single on CT scan; does not show evidence of invasion of the perirenal fat (T1-T2) on CT or IVU. Pt must have N0, M0 disease, be fit for surgery with a WHO performance status of less than 2. Pt must not have a solitary kidney, von Hippel-Lindau disease, multifocal disease, T3-T4 tumors, clinical presence of distant or lymphatic mets nor a WHO performance status of greater than 2.

Publication Information Expand/Collapse

2014

Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904

E Scosyrev;EM Messing;R Sylvester;S Campbell;H van Poppe European Urology 65(2):372-377;

PMid: PMID23850254 | PMC number: not available

Other Clinical Trials

SWOG Clinical Trial Number
S2312
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200